BioXcel Therapeutics (BTAI) Operating Margin (2022 - 2025)
Historic Operating Margin for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to 14518.37%.
- BioXcel Therapeutics' Operating Margin fell 73721100.0% to 14518.37% in Q3 2025 from the same period last year, while for Sep 2025 it was 6738.3%, marking a year-over-year decrease of 33715600.0%. This contributed to the annual value of 2967.56% for FY2024, which is 94804100.0% up from last year.
- As of Q3 2025, BioXcel Therapeutics' Operating Margin stood at 14518.37%, which was down 73721100.0% from 13210.0% recorded in Q2 2025.
- BioXcel Therapeutics' Operating Margin's 5-year high stood at 449714.29% during Q1 2022, with a 5-year trough of 28459.85% in Q3 2022.
- Moreover, its 4-year median value for Operating Margin was 7146.26% (2024), whereas its average is 19738.34%.
- Per our database at Business Quant, BioXcel Therapeutics' Operating Margin crashed by 2000000000bps in 2023 and then soared by 207016800bps in 2024.
- Quarter analysis of 4 years shows BioXcel Therapeutics' Operating Margin stood at 22224.37% in 2022, then soared by 76bps to 5285.9% in 2023, then skyrocketed by 46bps to 2866.94% in 2024, then tumbled by -406bps to 14518.37% in 2025.
- Its last three reported values are 14518.37% in Q3 2025, 13210.0% for Q2 2025, and 6011.31% during Q1 2025.